0.00
—
Close of 30 Oct 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Inyx
Its shares trade under the ticker IYXI. It has been listed since 19 February 2003. In the fiscal year to 31 December 2005, it reported revenue of $49.6m and a net loss of $31.0m. At that date it held total assets of $92.2m and shareholders' equity of −$30.4m.
Inyx, Inc. is pharmaceutical company, which develops and acquires niche pharmaceutical products and drug delivery systems for key therapeutic areas, including respiratory and dermatological applications. The company is headquartered in New York City, New York. The company went IPO on 2003-02-19. Its operations are focused on the development of both prescriptions, over the counter pharmaceutical products, and specialty consulting services. Also, the Company utilizes niche drug delivery capabilities to develop its own products. The product and service categories of the Company include Metered Dose Inhalers (MDIs) (CFC & HFA), Dry Powder Inhalers (DPIs), Metered Dose Pump Sprays (nasal and oral), Hydrocarbon Foam Aerosols, Saline Aerosols, Sterile Solutions/Injectables, Solid Dose, Formulation Services, Analytical Development Validation, Stability Services, Regulatory Support and Integrated Project Management.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 19 Feb 2003
- Employees
- 572
Leadership
Pay as last reported
- Ms. Jack KachkarChairman of the Board, Chief Executive Officer$445,000
- Steven HandleyPresident, since 2007$200,568
- Colin HunterExecutive Vice President, Chief Scientific Officer, since 2007$191,418
- Jay GreenExecutive Vice President and Director of Corporate Development, Director$275,000
- Stephen BeckmanVice President of Sales and Marketing and Commercial Development
- William KellyVice President of Investor Relations & Corporate Communications
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Inyx Inc has a focused sector in Health Care with a specific industry in Pharmaceuticals.
- The company employs 572 full-time employees and has been operational since its IPO in 2003.
- Inyx Inc develops niche pharmaceutical products and drug delivery systems for therapeutic areas including respiratory and dermatological applications.
Weaknesses
- The company's operations are limited to niche pharmaceutical products and drug delivery systems with no mention of broader market diversification.
- Inyx Inc's product categories are specific to respiratory and dermatological applications without indication of expansion into other therapeutic areas.
- The source description treats the company's operations as untrusted facts, indicating potential reliability issues in the provided information.
Opportunities
- The company could expand its product categories beyond respiratory and dermatological applications to new therapeutic areas.
- Inyx Inc may leverage its niche drug delivery capabilities to develop new products or enter new markets.
- The company's focus on both prescription and over-the-counter pharmaceutical products presents opportunities for market growth.
Threats
- The company's reliance on niche pharmaceutical products and drug delivery systems may limit its ability to adapt to market changes.
- Inyx Inc's untrusted source description could lead to inaccurate market analysis and strategic decisions.
- The company's limited operational scope in specific therapeutic areas may expose it to competition from larger pharmaceutical firms.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.